Petition seeks rethink of GLP-1 RAs compounding ban

Politicians are being urged to reconsider the decision to ban the compounding of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) until supply issues ease  Patients are calling for the government’s decision to prohibit the compounding of replicas of Ozempic (semaglutide) and Mounjaro (tirzepatide) from 1 October, to ensure access is maintained.   In a petition signed